Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC Announces Data Evaluating Novel AAV-Based Gene Therapy as a Potential Treatment for Alpha-1 Antitrypsin (AAT) Deficiency
Study Results Show That Vector DNA Persists at High Levels for 12 Months After One-Time Intramuscular Injection and Directs Sustained Expression of AAT Protein
View HTML
Toggle Summary AGTC Announces Preclinical Data Evaluating Cone-Specific Promoters for Use in Gene Therapy of Achromatopsia and Other Retinal Diseases
Study Results Further Validate Company's Technology Platform and Will be Used to Determine Optimal Components of ACHM-B3 Gene Therapy Clinical Development Program
View HTML
Toggle Summary AGTC and BCM Families Foundation Announce Collaboration to Develop AAV-Based Gene Therapy for Blue Cone Monochromacy
GAINESVILLE, Fla. and JUPITER, Fla. and CAMBRIDGE, Mass. , Jan. 06, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases,
View HTML
Toggle Summary AGTC Leadership to Present at Upcoming Scientific Conferences
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced
View HTML
Visionary science for life changing cures.